Stockscreener 앱 받기
7.95
2.19%
0.17
시간 외 거래:
7.92
-0.03
-0.38%
Vyome Holdings Inc 주식(HIND)의 최신 뉴스
Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity - biospace.com
Vyome Holdings Inc positive interim data from Phase 2 Study of VT-1953 in malignant fungating wounds - MarketScreener
Vyome’s VT-1953 shows significant reduction in cancer wound odor - Investing.com
Vyome’s VT-1953 shows significant reduction in cancer wound odor By Investing.com - Investing.com UK
Vyome Holdings Completes Merger with Vyome Therapeutics - MSN
Vyome Holdings completes merger with Vyome Therapeutics and files financials - Investing.com
Vyome Holdings, Embryyo Technologies Partner on AI Medtech - Medical Product Outsourcing
Vyome, Embryyo form partnership to pursue AI-enabled medical devices - Medical Economics
US-based Vyome signs MoU with India’s leading medical device innovation studio Embryyo - BioSpectrum India
Vyome And Embryyo Sign MoU To Develop AI-Enabled Medical Devices - Sahyadri Startups
Vyome Holdings, Inc. Signs MoU with Embryyo Technologies - MarketScreener
Vyome, India's Embryyo Sign MOU to Pursue AI Medical Device Market; Shares up Pre-Bell - MarketScreener
Vyome partners with Embryyo to enter AI-enabled medical device market - Investing.com
Vyome Signs MoU with Embryyo, India’s Leading Medical Device Innovation Studio - FinancialContent
Vyome Holdings expands at-the-market offering and appoints new auditor - Investing.com India
Vyome Holdings expands at-the-market offering and appoints new auditor By Investing.com - Investing.com South Africa
Vyome Holdings Amends Equity Distribution Agreement - TipRanks
Vyome Amends Equity Distribution Agreement with ReShape Lifesciences Inc. - AInvest
Vyome enters amendment no. 1 to equity distribution agreement - MarketScreener
Vyome to review strategic options for majority-owned Livechain By Investing.com - Investing.com Australia
Vyome to review strategic options for majority-owned Livechain - Investing.com
Unlocking Value Through Corporate Restructuring: Vyome's Strategic Pivot and the Future of Underfollowed Holdings - AInvest
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - MarketScreener
Vyome Debuts as HIND on Nasdaq, Strengthening US-India Innovation Ties - YourStory.com
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - MarketScreener
Vyome lists on Nasdaq as HIND after ReShape merger - Times of India
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - MarketScreener
Vyome Therapeutics Completes Merger With ReShape Lifesciences - MarketScreener
Vyome 2025 Q2 Earnings Strong Net Income Surge Despite Revenue Drop - AInvest
Vyome to begin trading as Vyome Holdings under HIND symbol By Investing.com - Investing.com Australia
Health Care Stocks Climb As Deals And Results Grab Attention - Finimize
Why Did ReShape Lifesciences Plunge 8.75% Amid Vyome Merger? - AInvest
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome therapeutics to list on nasdaq as HIND after reshape merger - Investing.com Canada
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - Asianet Newsable
Vyome to replace ReShape leadership as it prepares for Nasdaq listing - Investing.com Canada
Vyome to replace ReShape leadership as it prepares for Nasdaq listing By Investing.com - Investing.com South Africa
Vyome Announces New Board of Directors with Deep MIT and AI Ties - FinancialContent
Vyome Therapeutics: A High-Conviction Play at the Intersection of Biotech and AI Innovation - AInvest
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Shareholders Approve Vyome Merger, Shares to Commence Trading on Nasdaq as Vyome Holdings, Inc. - AInvest
ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics - MarketScreener
ReShape Lifesciences Merger at Critical Stage: Stockholders Must Approve Asset Sale by August 7 - Stock Titan
ReShape Lifesciences Strategic Transformation: Board and Proxy Advisors Unite Behind Vyome Merger - Stock Titan
AUTOCANADA ANNOUNCES CONFERENCE CALL AND WEBCAST DETAILS FOR Q2 2025 FINANCIAL RESULTS - The Globe and Mail
ReShape Lifesciences Slashes Payroll by 23.4% While Fast-Tracking Vyome MergerKey Details Revealed - Stock Titan
ReShape Lifesciences Stock Soars On Distribution Agreement With Recon Supply, Draws Retail Applause By Stocktwits - Investing.com India
ReShape Lifesciences: Intellectual Property and Merger Synergies Position the Company for Long-Term Growth Amid Industry Shifts - AInvest
ReShape Lifesciences And Kiora Pharma Impress Investors, Dollar General Uplifts Outlook - Finimize
ReShape Lifesciences Stock Soars On Regulatory Certification For Medical Devices In EU, UK: Retail Eyes Fair Valuation - Stocktwits
ReShape Lifesciences Inc. Reports First Quarter 2025 Financial Results and Strategic Updates - Nasdaq
ReShape secures exclusive deal for neuromuscular rehab tech - Investing.com India
RSLS stock touches 52-week low at $0.34 amid market challenges - Investing.com
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update - GlobeNewswire
ReShape Lifesciences Inc. SEC 10-K Report - TradingView
ReShape Lifesciences shareholders approve key proposals - Investing.com
RSLS stock touches 52-week low at $0.49 amid sharp annual decline - Investing.com
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology - MarketScreener
RSLS stock touches 52-week low at $0.87 amid market challenges - Investing.com
1.40%
자본화:
|
볼륨(24시간):